摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-甲氧基-2-吡啶基)乙腈 | 149489-09-8

中文名称
(3-甲氧基-2-吡啶基)乙腈
中文别名
——
英文名称
2-(3-methoxypyridin-2-yl)acetonitrile
英文别名
(3-methoxypyridin-2-yl)acetonitrile;(2-methoxy-3-pyridyl)methyl cyanide;2-[(3-methoxy)pyridyl]acetonitrile;(3-methoxy-2-pyridin-2-yl)acetonitrile
(3-甲氧基-2-吡啶基)乙腈化学式
CAS
149489-09-8
化学式
C8H8N2O
mdl
——
分子量
148.164
InChiKey
OJYATSHMGUIGBW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    265.5±25.0 °C(Predicted)
  • 密度:
    1.115±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    45.9
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090

SDS

SDS:91258f85010e80cdeb345630baa095ff
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3-甲氧基-2-吡啶基)乙腈氢气lithium diisopropyl amide 作用下, 以 四氢呋喃叔丁醇 为溶剂, -78.0~20.0 ℃ 、101.33 kPa 条件下, 反应 0.25h, 生成 (+/-)-tert-butyl 4-amino-3-(3-methoxypyridin-2-yl)butanoate
    参考文献:
    名称:
    SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF
    摘要:
    本申请涉及新型取代N-芳基乙基-2-芳基喹啉-4-羧酰胺衍生物,其制备方法,其单独或组合用于治疗和/或预防疾病的用途,以及其用于生产治疗和/或预防疾病的药物的用途,特别是用于治疗和/或预防纤维化和炎症性疾病。
    公开号:
    US20200031775A1
  • 作为产物:
    描述:
    (3-甲氧基-2-吡啶)-甲醇氯化亚砜 、 sodium carbonate 作用下, 以 甲醇 为溶剂, 生成 (3-甲氧基-2-吡啶基)乙腈
    参考文献:
    名称:
    Method for inhibition of HIV related viruses
    摘要:
    揭示了治疗艾滋病、抑制HIV及相关病毒复制以及使用硫脲衍生物化合物或其盐的配方。还揭示了新型硫脲衍生物化合物。
    公开号:
    US05593993A1
点击查看最新优质反应信息

文献信息

  • Novel piperidine compouds and drugs containing the same
    申请人:——
    公开号:US20030220368A1
    公开(公告)日:2003-11-27
    The present invention provides a novel compound having a superior Na + channel inhibition activity. Namely, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. 1 In the formula, the ring A represents a ring represented by the formula: 2 (wherein R 1 represents a hydrogen atom etc.; and R 2 represents indicates a hydrogen atom and the like) etc.; W represents an optionally substituted C 1-6 alkylene group etc.; Z represents an optionally substituted C 6-14 aromatic hydrocarbon cyclic group etc.; and l represents an integer from 0 to 6.
    本发明提供了一种具有优越的Na + 通道抑制活性的新型化合物。即提供了由以下式(I)表示的化合物,其盐或其水合物。 在该式中,环A表示由以下式表示的环: (其中R 1 表示氢原子等;R 2 表示表示氢原子等)等;W表示可选地取代的C 1-6 烷基等;Z表示可选地取代的C 6-14 芳香烃环基等;l表示0到6的整数。
  • [EN] 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS<br/>[FR] DÉRIVÉS DE 1-HÉTÉROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE ET LEURS UTILISATIONS À TITRE DE MODULATEURS DE PDE9A
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2009121919A1
    公开(公告)日:2009-10-08
    The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.
    该发明涉及新型1,6-二取代吡唑吡嘧啶酮,化学式(I),其中Hc是一个单环、双环或三环杂环基团,其环成员为碳原子和至少1个,优选1个、2个或3个来自氮、氧和硫的杂原子,其以-S(O)r-的形式存在,其中r为0、1或2,所述杂环基团是或包括1个非芳香、饱和或部分不饱和的单环环,其中至少包含1个杂原子作为环成员,所述杂环基团通过所述至少包含1个杂原子作为环成员的非芳香、饱和或部分不饱和的单环环与支架相结合。根据该发明的一个方面,新化合物用于制造药物,特别是用于治疗感知、注意力、学习或记忆缺陷相关疾病的药物。新化合物还用于制造治疗阿尔茨海默病的药物。
  • COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS
    申请人:Fuchs Klaus
    公开号:US20120115863A1
    公开(公告)日:2012-05-10
    The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein Ā is selected from the group A 1 consisting of a C 3 -C 8 -cycloalkyl group or a C 4 -C 8 -cycloalkenyl group, whereby the members of C 3 -C 8 -cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C 4 -C 8 -cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.
    该发明涉及具有以下结构的新型环烷基或环烯基取代的吡唑吡咪啉酮化合物(I),其中Ā选自A1组中的C3-C8环烷基或C4-C8环烯基,其中C3-C8环烷基组成员选自环丙基、环丁基、环戊基、环己基、环庚基和环辛基;而C4-C8环烯基组成员选自环丁烯基、环戊烯基、环己烯基、环庚烯基、环辛烯基、环戊二烯基、环己二烯基、环庚二烯基、环辛二烯基、环庚三烯基、环辛烷基、环辛四烯基。这些新化合物可用于制造药物,特别是用于改善患者感知、注意力、学习和/或记忆的药物。从化学上讲,这些化合物被描述为在吡唑吡咪啉酮的1位上直接连接有环烷基基团,并且在6位上通过一个可选取代的亚甲基桥连接有第二取代基。该发明的进一步方面涉及一种制造这些化合物的方法以及它们用于生产药物的用途。
  • [EN] IMMUNOPROTEASOME INHIBITORS<br/>[FR] INHIBITEURS D'IMMUNOPROTÉASOME
    申请人:PRINCIPIA BIOPHARMA INC
    公开号:WO2019099576A1
    公开(公告)日:2019-05-23
    Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    本文提供了化合物,如式(I)的化合物,或其药用可接受盐,这些化合物是免疫蛋白酶体(如LMP2和LMP7)抑制剂。本文描述的化合物可用于治疗通过抑制免疫蛋白酶体可治疗的疾病。本文还提供了含有这些化合物的药物组合物和制备这些化合物的方法。
  • Compounds and methods for inhibition of HIV and related viruses
    申请人:Medivir AB
    公开号:US05714503A1
    公开(公告)日:1998-02-03
    Treatment of AIDS, inhibition of the replication of HIV and related viruses thereof, and formulations using thiourea derivative compounds or salts thereof is disclosed. Also disclosed are novel thiourea derivative compounds.
    本发明揭示了治疗艾滋病、抑制HIV及其相关病毒复制以及使用硫脲衍生物化合物或其盐的配方。此外,本发明还揭示了新的硫脲衍生物化合物。
查看更多